TrialBreast cancer research : BCR2025

Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial.

Andrea Vethencourt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.